← Eichor
Study identifier: NCT07362875 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy

Condition: Myotonic Dystrophy  ·  Sponsor: Wake Forest University Health Sciences

PhaseN/A
Planned participants75
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersYes

About this study

Myotonic dystrophy (dystrophia myotonica; DM), the most prevalent form of muscular dystrophy in adults, is characterized by progressive myopathy, myotonia, and multi-systemic involvement. DM causes severe disability and profoundly affects the patient's quality of life. Currently, no effective treatments are available that alter the course of the disease, but ongoing clinical trials are underway.

This description comes directly from the study's public registry record.

Talk to the study team

Elizabeth (Gracie) G Hilber  ·  336-716-4163  ·  Elizabeth.Hilber@Advocatehealth.org

Constance Linville  ·  704-355-2000  ·  Martha.Linville@advocatehealth.org

Always discuss trial participation with your own doctor first.

Locations (1)

Wake Forest University Health SciencesWinston-Salem, North Carolina, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07362875